Innovative Robotic Ultrasound Scanning Revolutionizes Dialysis Care in Groundbreaking CANSCAN Trial

Transforming Dialysis Care: The CANSCAN Trial

Vexev, an Australian med-tech company, and U.S. Renal Care have made significant strides in the realm of dialysis treatment by successfully concluding the enrollment of 120 patients in the CANSCAN clinical trial (NCT06691672). This groundbreaking study employs the innovative semi-autonomous VxWave™ Ultrasound Imaging System for arteriovenous (AV) fistula mapping within dialysis clinics, marking a pivotal advancement in medical imaging technology.

What is the CANSCAN Trial?

The CANSCAN trial serves as a multi-center feasibility study aimed at evaluating the effectiveness of the VxWave Ultrasound Imaging System. This system is designed specifically for vascular imaging, seeking to enhance the process of creating permanent vascular access for patients with chronic kidney disease. By allowing vascular mapping to occur directly within dialysis facilities, the technology promises greater efficiency and convenience for patients in need of timely treatments.

As explained by Dr. Varshi Broumand, Principal Investigator of the study, the ability to conduct ultrasound scans during a patient’s clinic visit can help overcome one of the largest obstacles in establishing vascular access. This capability has the potential to streamline the process, eliminating the need for additional imaging appointments, thereby improving the overall patient experience.

How Does the VxWave Ultrasound Imaging System Work?

The VxWave Ultrasound Imaging System is nothing short of revolutionary. Utilizing advanced robotics, machine learning, and state-of-the-art ultrasound signal processing, the system generates a 3D vascular model enriched with detailed reports that provide pivotal insights into optimal vascular access locations. By advancing this technology, Vexev aims to transform the way medical imaging is performed, making it more accessible and effective.